This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
BMY vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. VRTX: Which Stock Is the Better Value Option?
Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $55.78, denoting a -0.89% change from the preceding trading day.
Top Analyst Reports for Visa, Linde & Thermo Fisher Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Linde plc (LIN) and Thermo Fisher Scientific Inc. (TMO), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Autoscope Technologies Corporation (AATC).
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
by Zacks Equity Research
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
Bristol Myers (BMY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Why Is Vertex (VRTX) Down 8.6% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
by Zacks Equity Research
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
by Zacks Equity Research
REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHD
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPHD
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
by Derek Lewis
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.